Zhejiang Jolly Pharmaceutical board adjusts governance, approves new policies

On September 5, 2025, Zhejiang Jolly Pharmaceutical's eighth board of directors held its eighth extraordinary meeting, approving changes to its audit committee and strategic and ESG committee. Ms. Shen Yuehong resigned as a non-independent director and member of the strategic and ESG committee, but was subsequently elected as an employee representative director and re-appointed to the strategic and ESG committee. The board confirmed the audit committee members, Mr. Zhu Jian, Ms. Wang Ping, and Mr. Zheng Xuegen, with Mr. Zhu Jian as the convener.

Concurrently, the company held its first extraordinary general meeting of shareholders for 2025, where shareholders approved revisions to several key internal documents. These included amendments to the "Articles of Association," "Rules of Procedure for Shareholder Meetings," "Rules of Procedure for Board Meetings," "Independent Director System," "Remuneration Management System for Directors and Senior Management," "Management System for Raised Funds," "External Guarantee Management System," "Related Party Transaction Management Measures," "External Investment Management System," and "Cumulative Voting Management System." Additionally, the "Rules of Procedure for Supervisory Board Meetings" and the "Remuneration Management System for Directors and Supervisors" were abolished.

All resolutions passed at the board meeting and the extraordinary general meeting were confirmed to be in compliance with relevant laws and regulations, with lawyer opinions affirming the legality of the proceedings and results.